Role of tumor necrosis factor-alpha (C-863A) polymorphism in pathogenesis of inflammatory bowel disease in Northern India

被引：16
作者：
Dinesh K. Ahirwar
Pravin Kesarwani
Ranjana Singh
Uday Chand Ghoshal
Rama Devi Mittal
机构：
[1] Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, Raebareli Road
[2] Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, Raebareli Road
来源：
Journal of Gastrointestinal Cancer | 2012年 / 43卷 / 2期
关键词：
Crohn's disease; Haplotype; Inflammatory bowel disease; Interleukin-10; Interleukin-4; Polymorphism; Tumor necrosis factor-alpha; Ulcerative colitis;
D O I：
10.1007/s12029-010-9238-9
中图分类号：
学科分类号：
摘要：
Objective: Inflammatory bowel diseases (IBDs), namely ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic and idiopathic inflammatory conditions of gastrointestinal tract that are immunologically mediated. Single nucleotide polymorphisms in cytokine genes have been reported to modulate inflammation. Therefore, we analyzed the association of pro/anti-inflammatory cytokine genes polymorphism with IBD susceptibility. Methods: Genotyping of interleukin (IL)-4 repeat polymorphism in intron-3, IL-10 (G-1082A and C-819T), and tumor necrosis factor-alpha (TNF-A) (-1031 T>C, -863 C>A, and -857 C>T) was performed in 153 patients with IBD and in 207 controls. Results: TNF-A -863 AA genotype was associated with enhanced IBD susceptibility (odds ratio (OR), 4.82; 95% confidence interval (CI), 2.60-8.96), more so for UC (OR, 5.79; 95% CI, 2.99-11.21), Crohn's disease [CD] (OR, 3.13; 95% CI, 1.16-8.47). TNF-A T/C/T (OR, 4.40; 95% CI, 1.64-11.81) and C/A/C (OR, 4.15; 95% CI, 2.48-6.96) haplotypes were associated with increased IBD risk. The frequency of IL-4, B2 carrier (B1/B2+B2/B2) was significantly lower in left-sided UC (17.1%) than proctosigmoiditis (47.6%); p, 0.016. In contrast, TNF-A -863 AA genotype frequency was much higher in pancolitis (45.5) than in proctosigmoiditis (14.2); p, 0.037. Variant genotypes of IL-4 (B1/B2+B2/B2) were absent in colonic type CD. IL-10 polymorphisms did not demonstrate any association with IBD. None of the polymorphisms were associated with steroid treatment and surgery. Conclusion: The present study depicts that high-producing genotype of TNF-A (-863 AA) was associated with increased risk of IBD more so with UC. Similarly, combined effect of TNF-A polymorphisms in haplotype analysis demonstrated additively increased risk of IBD. © Springer Science+Business Media, LLC 2011.
引用
收藏
页码：196 / 204
页数：8
相关论文
共 33 条
  • [1] Sood A., Midha V., Epidemiology of inflammatory bowel disease in Asia, Indian Journal of Gastroenterology, 26, 6, pp. 285-289, (2007)
  • [2] Das K., Et al., Crohn's disease in India: A multicenter study from a country where tuberculosis is endemic, Dig Dis Sci, 54, pp. 1099-1107, (2008)
  • [3] Binder V., Genetic Epidemiology in Inflammatory Bowel Disease, Digestive Diseases, 16, 6, pp. 351-355, (1998)
  • [4] Hendrickson B.A., Gokhale R., Cho J.H., Clinical aspects and pathophysiology of inflammatory bowel disease, Clinical Microbiology Reviews, 15, 1, pp. 79-94, (2002)
  • [5] Podolsky D.K., Inflammatory bowel disease, New England Journal of Medicine, 347, 6, pp. 417-429, (2002)
  • [6] Braat H., Stokkers P., Hommes T., Cohn D., Vogels E., Pronk I., Spek A., Van Kampen A., Van Deventer S., Peppelenbosch M., Hommes D., Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients, Journal of Molecular Medicine, 83, 8, pp. 601-609, (2005)
  • [7] Bouma G., Strober W., The immunological and genetic basis of inflammatory bowel disease, Nature Reviews Immunology, 3, 7, pp. 521-533, (2003)
  • [8] Autschbach F., Et al., Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in non-inflamed gut and Crohn's disease, Virchows Arch, 426, 1, pp. 51-60, (1995)
  • [9] Murch S.H., Braegger C.P., Walker-Smith J.A., MacDonald T.T., Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease, Gut, 34, 12, pp. 1705-1709, (1993)
  • [10] Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., Vilien M., Strom M., Danielsson A., Verbaan H., Hellstrom P.M., Magnuson A., Curman B., Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study, Gastroenterology, 128, 7, pp. 1805-1811, (2005)
1234